default author photo

Tanios Bekaii-Saab

Mayo Clinic Hospital - Phoenix - Division of Medical Oncology

Phoenix, AZ

United States

SCHOLARLY PAPERS

4

DOWNLOADS

315

TOTAL CITATIONS

3

Scholarly Papers (4)

1.

Regorafenib Dose-Optimization Study (ReDOS): A Phase 2 Randomized Study to Evaluate Dosing Strategies for Regorafenib in Patients with Refractory Metastatic Colorectal Cancer - An ACCRU Network Study

Number of pages: 28 Posted: 28 Jan 2019
Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, Mayo Clinic, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, Roswell Park Comprehensive Cancer Center, Vanderbilt University - Department of Medicine, Mayo Clinic, Mayo Clinic, Minnesota Oncology, Wake Forest University - Comprehensive Cancer CenterWake Forest University - Department of Cancer Biology, Harvard University - Dana-Farber Cancer Institute, Mayo Clinic, University of Washington, Washington University in St. Louis - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, University of Washington - School of Medicine, Mayo Clinic, Memorial Sloan Kettering Cancer Center - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center and West Cancer Center and Research Institute
Downloads 140 (530,816)
Citation 3

Abstract:

Loading...

Refractory metastatic colorectal cancer, Regorafenib, Dose-optimization, Phase 2, Dosing strategies

2.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Number of pages: 28 Posted: 15 May 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Universita di Cagliari - University Hospital of Cagliari, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, IRCCS Humanitas Research Hospital, Università Campus Bio-Medico di Roma, Seoul National University - Seoul National University Bundang Hospital, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, Sapienza University of Rome, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Clinico Humanitas, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University Hospital Frankfurt, University of Foggia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 75 (837,727)

Abstract:

Loading...

cholangiocarcinoma, durvalumab, immunotherapy, real-world evidence, biliary tract cancer, advanced disease

3.

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy

Number of pages: 31 Posted: 03 Dec 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Pisa, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Universita di Cagliari - University Hospital of Cagliari, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, affiliation not provided to SSRN, University of Florida, Università Campus Bio-Medico di Roma, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), affiliation not provided to SSRN, AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, University of Glasgow, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, Polytechnic University of Marche, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, Sapienza University of Rome, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital de Santa Maria, affiliation not provided to SSRN, University of Padua, Humanitas University, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Foggia, affiliation not provided to SSRN, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, University of Pisa, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Vita Salute San Raffaele University, IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 52 (1,052,702)

Abstract:

Loading...

Biliary Tract Cancer, gut micobiome, antibiotic therapy, Immune checkpoint inhibitors

4.

ZEBRA: An IRCI/ACCRU (RU021502I) Multicenter Phase II Study of Pembrolizumab in Patients With Advanced Small Bowel Adenocarcinoma (SBA)

Number of pages: 38 Posted: 25 Jan 2021
Division of Oncology, Washington University, Mayo Clinic, University of Texas at Houston - MD Anderson Cancer Center, Department of GI Oncology, Roswell Park Comprehensive Cancer Center, Georgetown University, Rapid City Regional Hospital, Mayo Clinic, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, Mayo Clinic, National Cancer Institute, University of Glasgow and Mayo Clinic - Department of Oncology
Downloads 48 (1,109,210)

Abstract:

Loading...